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Abstract In recent years RNA interference (RNAi) has
become a useful genetic tool to downregulate candidate
disease genes for which pharmaceutical inhibitors are not
available. In combination with viral vectors to trigger
RNAi in the mammalian body, it allows the localized and
speciﬁc manipulation of the expression of single or mul-
tiple genes in vivo. The MAP kinases ERK1 and ERK2 are
involved in the transduction of extracellular signals to
nuclear effectors. A role for ERKs has been proposed in the
adult brain in mediating neuronal functions, as for fear
learning in the lateral amygdala. To study the role of ERK
in anxiety disorders characterized by disturbed fear learn-
ing processes we developed Erk-speciﬁc RNAi tools and
tested the efﬁcacy of a viral Erk2 vector in the adult mouse
brain. We found shRNAs that showed silencing of either
both ERK1/2 or only ERK2. In particular, our analysis
showed that an Erk2-speciﬁc shRNA reduced the activity
of this gene at comparable efﬁciency both in vitro and
in vivo. This reagent provides a useful tool to study the
role of ERK2, for which small molecule inhibitors are not
available, in the development of anxiety and other psy-
chiatric disorders.
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Introduction
The extracellular signal-regulated kinase/mitogen-acti-
vated protein kinase (ERK/MAPK) pathway is a signaling
cascade involved in diverse cellular functions such as
growth, proliferation, and differentiation [1]. Recently, via
pharmacological inhibition of ERKs’ upstream activators
MEK1 and MEK2, a role for ERK1 and ERK2 was also
proposed in mature neurons of the rat lateral amygdala
(LA) in fear learning [2]. Several brain disorders, like
anxiety disorders, are characterized by disturbed fear
learning processing [3]. Therefore, the analysis of the
molecular pathways responsible for normal and patholog-
ical development of fear learning and the search for
clinically effective therapeutic tools are highly relevant.
Via the analysis of knockout mice for Erk1 and Erk2, it
was suggested that the lack of ERK1 does not impair
emotional learning [4], while the partial inactivation of
ERK2 can affect long-term fear learning [5]. But the
simultaneous and ubiquitous expression of Erk1 and Erk2
genes in many regions of the adult murine CNS [6] sug-
gests that the analysis of single knockout animals for these
genes is not sufﬁcient to clarify their speciﬁc role, due to
their potential redundancy which could mislead data
interpretation. Thus, classical pharmacology as well as
knockout technologies encounter limitations due to: (i) the
lack of pharmacological inhibitors targeting speciﬁcally the
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DOI 10.1007/s12033-008-9125-9ERKs; (ii) the laborious methods necessary for the gener-
ation and analysis of single or multiple knockout mice; (iii)
the limited number of region-speciﬁc promoter regions to
allow restricted loss-of-function studies. The discovery of
RNA interference (RNAi) can help in mitigating such
limitations, allowing the silencing of the expression of
single or multiple genes in an efﬁcient and quick manner
[7]. In addition, the possibility of using short interfering
RNA (siRNA) [8] or short hairpin RNA (shRNA) [9]t o
trigger RNAi in cells, in combination with viral vectors to
perform somatic genetic manipulation, facilitates the spe-
ciﬁc loss-of-function analysis in selected brain areas [10].
In particular, adeno-associated virus (AAV) reagents have
been successfully used to perform gene transfer in the brain
via stereotaxic injection [11, 12], as they show several
advantages: (i) adaptable diffusion of the vector at the
injection site by using different virus serotypes [13]; (ii)
predominant infection of neurons rather than glia cells
[14]; (iii) very low integration efﬁciency (0.1–0.5%) in the
genome of infected cells [15].
In this study, we show the selection and in vitro vali-
dation of shRNAs to target and downregulate both Erk1/2
simultaneously, or speciﬁcally Erk2, leaving Erk1 unaf-
fected. The further in vivo analysis of AAV-mediated
downregulation of Erk2 conﬁrmed our shRNA as a valid
tool for the local inhibition of this gene in neurons of the
adult mouse brain. This opens the avenue for further
studies to analyze the region-speciﬁc contribution of ERK2
to the development of anxiety and other psychiatric
disorders.
Materials and Methods
Selection and Validation of shRNA In Vitro
A Bluescript plasmid containing the human U6 promoter
from pSHAG [16] was opened with BseRI/BamHI and
ligated with an Erk2-speciﬁc oligonucleotide pair (Erksh4)
or an Erk1/2-speciﬁc oligonucleotide pair (Erksh6) (for
sequences see Fig. 1b). The LacZ-speciﬁc shRNA vector
has been described previously [17]. All plasmids were
grown in DH5a, isolated with QIAgen plasmid Maxiprep
columns and the integrity of the promoter and shRNA
regions was conﬁrmed by DNA sequencing. Mouse F1 ES
cells (IDG3.2) were used for transient transfections. ES
cells were grown in DMEM medium (Gibco) containing
12.5% FCS, 20 mM HEPES pH 7.2, 0.1 mM MEM non-
essential amino acids (Gibco, Cat. No.: 11140–035),
0.1 mM 2-mercaptoethanol, and 90 ll LIF (10
7 U/ml,
Chemicon) on gelatine coated culture dishes. About
2 9 10
6 cells were electroporated with each shRNA plas-
mid and cultivated for 48 h. Cells were then homogenized
in lysis buffer (2% SDS, 50 mM Tris pH 6.8, 50 mM DTT,
10% Glycerol, Protease inhibitor cocktail (Roche, Cat. No.:
11697498001)), and protein concentrations were deter-
mined with the BCA test (Pierce) in comparison to BSA as
standard; 20 lg of each sample were heat denatured, sep-
arated on a SDS-PAGE gel, and blotted on PVDF
membranes (Pall). Membranes were blocked in 3% BSA in
phosphate-buffered saline with 0.1% Tween 20 (PBS-T)
for 24 h at 4C, incubated with rabbit anti-ERK1/2
(1:1000, Cell Signaling Technology) 1 h at RT, washed in
PBS-T, and incubated with HRP-goat anti-rabbit (1:1000,
Jackson ImmunoResearch) 1 h at RT. After washing, sig-
nals were visualized with ECL reagents (Amersham
Biosciences) and ﬁlms were scanned and processed with
Adobe Photoshop. For shRNAs that showed performance
in Western blot experiments real-time qRT-PCR analysis
was performed in addition. Brieﬂy, total RNA was
extracted from cells with the Invisorb RNA Kit (Invitek),
cDNA synthesis was performed with ABI HighCapacity
cDNA reagents and qRT-PCR (Quantace SybrGreen qPCR
mix) was run with an ABI 7900HT machine.
Construction of rAAV Vector Plasmid
Two expression cassettes—one for the yellow ﬂuorescent
protein Venus and one either for the shRNA targeting Erk2
or LacZ—were cloned into the pAAV-MCS plasmid
(Stratagene) to obtain the expression plasmid CMV-Venus-
U6shRNA. Venus is a yellow variant of the green
Fig. 1 Schematic drawings of shRNA constructs for in vitro/in vivo
studies. a For in vitro studies, the short hairpin RNAs were cloned in
pBluescript vector under the control of the U6 promoter (U6). b
Sequences of the hairpins tested for their downregulation efﬁciency
via Western blot, after electroporation of the shRNA vector constructs
into ES cells. Sequences of the hairpin-loops are underlined. c
Schematic representation of the recombinant AAV vector genome
AAV-CMV-Venus-U6shRNA. The two expression cassettes for the
reporter Venus and the shRNA are separated by a 1.0 kb stuffer
element and the genome is ﬂanked by two 141 bp inverted terminal
repeats. ITR inverted terminal repeats; CMV cytomegalovirus pro-
moter; intron: b-globin intron; Venus: yellow ﬂuorescent protein
Venus; pA: human growth hormone polyA signal; stuffer: stuffer
element; U6: U6 promoter; LacZsh: control hairpin; Erksh4: hairpin
against Erk2
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bodies [18]. The expression of the reporter gene and the
shRNA are driven by the RNA polymerase II-driven CMV
and the RNA polymerase III-driven U6 promoter, respec-
tively. The expression cassettes are separated by a non-
functional stuffer sequence cloned from the 30 end of the b-
galactosidase gene to obtain an optimal AAV genome size
of 4.7 kb.
Production of rAAV Vector
For vector preparation, ten 100-mm petri dishes of
HEK293-derived AAV-293 cells (Stratagene) were trans-
fected by the calcium phosphate technique with 300 lgo f
plasmid DNA (expression plasmid, pHelper and pAAV-
RC, 100 lg each) according to the AAV Helper-Free
System manual (Stratagene). After 4 days of incubation,
cells were harvested and lysed two times by freeze and
thaw technique. Afterward the viral particles were sepa-
rated from the cell debris by centrifugation.
Puriﬁcation of rAAV Vector
Virus suspensions were puriﬁed by a single-step column
puriﬁcation [19]; modiﬁed protocol) using a heparin-aga-
rose matrix. Viral particles were washed twice with PBS,
pH 7.4 and eluted in PBS, pH 7.4 plus 0.5 M NaCl. This
eluate was desalted and concentrated with an Amicon Ultra
centrifugal ﬁlter device (Millipore, 100 K NMWL).
Characterization of Viral Vectors
The purity of viral preparations was assessed by electro-
phoresis on SDS-PAGE gels. Total protein was stained by
the Coomassie method. Determination of the genomic titer
was achieved by dot blot analysis: a viral sample was
degraded with protease K and loaded on a nitrocellulose
membrane. As control, a dilution series of viral cloning
plasmids was loaded. For autoradiography, a probe
matching the Venus-coding region of the viral genome was
used. The in vitro transduction efﬁciency of viral vectors
was determined by incubation of HT1080 cells with a
diluted virus preparation. Infected cells expressing the
Venus reporter gene were identiﬁed by ﬂuorescence
microscopy.
Viral Injections and Tissue Preparation
for Immunohistochemistry
C57BL/6J adult male mice (Charles River) were anesthe-
tized and stereotaxically injected bilaterally with 1 ll/side
of AAV preparation into the amygdala. Injections were
performed at 0.25 ll/min rate and injectors were left in
place for one additional min to allow diffusion of the virus
from the tip. Injection coordinates [20] were: -1.7 mm
anteroposterior, ±3.4 mm mediolateral, and -4.0 mm
dorsoventral. After 1 week, mice were killed and perfused
with 4% paraformaldehyde; brains were removed, post-
ﬁxed overnight, and cryoprotected in 25% sucrose in PBS.
Coronal cryosections (30 lm) were cut through the area of
the amygdala and kept in cryoprotective solution at -20C
until processed. Experiments involving animals were car-
ried out in accordance with national and institutional
guidelines.
Immunoﬂuorescent-Immunohistochemistry (IF-IHC)
and in situ Hybridization (ISH)
For the IF-IHC co-localization studies, sections were
washed in PBS and incubated with chicken anti-green
ﬂuorescent protein antibody (anti-GFP, Aves Lab, 1:500),
together with either the speciﬁc neuronal marker anti-
NeuN (mouse, 1:200, Chemicon) or the speciﬁc glial
marker anti-S100b (mouse, 1:1000, Sigma) in 10% normal
goat serum/0.5% Triton X-100 in PBS, overnight at 4C.
On the second day, sections were washed and incubated
overnight at 4C with the secondary ﬂuorophore-conju-
gated antibodies (FITC-anti-chicken, Aves Lab, and
TRITC-anti-mouse IgG1, Southern Biotech, both 1:200)
and with the nuclear marker DAPI (Sigma). On the third
day, sections were washed and mounted onto poly-L-lysine-
coated slides for confocal microscopy analysis. For the IF-
IHC/ISH co-localization studies, the plasmid containing
the cDNA for the Erk2 probe was linearized with the
appropriate enzyme, puriﬁed (PCR puriﬁcation Kit, QIA-
gen), and the DIG-labeled probe was prepared by in vitro
transcription with DIG RNA Labeling Kit (SP6/T7)
(Roche), following manufacturer’s instructions. After
DNase I (Roche) treatment, the probes were puriﬁed by the
RNeasy Clean up protocol (QIAgen) and measured in a
dot-blot assay, comparing serial dilutions of probe to DIG-
labeled control RNA standards. For the ISH procedures,
brieﬂy: free-ﬂoating sections were rinsed in PBS and
endogenous peroxidase quenched with 30 min incubation
in 0.3% H2O2 in PBS. Sections were then rinsed in PBS
and incubated 15 min in 59 SSC (0.75 M NaCl, 0.75 M
Na-citrate). Afterward, they were incubated 1 h at 58Ci n
pre-hybridization solution (59 SSC, 50% formamide, pH
7.5 with HCl, 50 lg/ml salmon sperm) and overnight at
58C in hybridization solution (pre-hybridization solution
with 500 ng/ml of DIG-labeled probe). On the second day,
sections were washed 1 h at 65Ci n2 9 SSC, then rinsed
in PBS, and blocked 30 min in PBS-BB (PBS with 1%
BSA, 0.2% powdered skim milk, 0.3% Triton X-100).
Afterward, they were incubated 1 h in HRP-conjugated
anti-DIG antibody (Roche), washed in PBS and in PBST
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signal, sections were incubated 20 min in Tyramid Signal
Ampliﬁcation solution (TSA, Perkin Elmer) (dilution 1:50
in its own diluent solution). They were then rinsed in
Maleic acid buffer (MB, 0.1 M Maleic acid, 0.15 NaCl, pH
7.5 with NaOH) and incubated 30 min in Neutravidin
solution (Pierce) (dilution 1:750 in Maleic acid blocking
buffer (1% blocking reagent, Roche, in MB)). After a wash
in MB, sections were rinsed in Detection buffer (0.1 M
Tris–HCl, pH 9.5; 0.05 M MgCl2; 0.1 M NaCl) and
developed in Developing solution (0.5 mg/ml NBT,
0.375 mg/ml BCIP (Roche) in Detection buffer). When a
clear signal was visible, sections were washed in PBS and
incubated overnight with chicken anti-GFP antibody (as
above, 1:500) in 10% goat serum/0.5% TX-100 in PBS.
After washing in PBS, sections were incubated overnight
with the secondary ﬂuorescent-conjugated antibody (FITC-
anti-chicken, as above, 1:200) in 10% goat serum/0.5%
TX-100 in PBS. After washing, sections were mounted on
poly-L-lysine-coated slides, covered with anti-fading
AquaPolyMount (Polysciences) and coverslips, and dried
before confocal microscopy analysis.
Microscopy Data Analysis
The analysis was performed using a confocal microscope
(Olympus, equipped with the FluoView1000 Software),
scoring through amygdala’s sections, from anterior to
posterior levels, on both left and right sides, in at least two
brains for each injected viral vector.
Results
Development and in vitro Test of Erk-Speciﬁc shRNA
Vectors
Short hairpins targeting Erk1/2 or Erk2 alone were cloned
into an expression vector under the control of the human
U6 promoter (Fig. 1a, b). These vectors were electropo-
rated into embryonic stem (ES) cells to test their gene
silencing efﬁciency in vitro. Two days after transfection
cells were lysed and the levels of ERK1 and ERK2 pro-
teins were analyzed by western blotting of protein
Fig. 2 Western blot and qRT-PCR analysis of downregulation
efﬁciency of shRNA vectors. a ShRNA vectors were tested in ES
cells, as described in section ‘‘Materials and Methods’’; Western blot
analysis revealed that Erksh4 and Erksh6 downregulated speciﬁcally
ERK2, as compared to control samples (‘‘Ctrl’’). b Erksh4 and Erksh6
were further analyzed with qRT-PCR; the results conﬁrmed the
speciﬁc and signiﬁcant reduction in ERK2 expression for Erksh4,
while Erksh6 reduced ERK2, but affected also Erk1 mRNA level, and
was therefore excluded from further experiments. Error bars show
minimal and maximal results from triplicate measurements
Fig. 3 Tropism and downregulation efﬁciency of Erksh4 in vivo. a
Schematic drawing of the amygdala at approximately -1.82 mm
from bregma (according to (Franklin and Paxinos, 1997)). b, c
Tropism of the virus. Representative photomicrographs of a portion of
the LA (blue square in (a)) which show the site of injection,
immunostained for YFP (green) and NeuN (red) (b) and for YFP
(green) and S100b (red) (c); ounterstaining with DAPI (blue) shows
the single-cell nuclei. (d0, d00, d000) Higher magniﬁcation of labeled
cells (white square (D) in (b)) to show the single signals for NeuN (d0)
and venus (d00) and the yellow color of their ‘‘merge’’ (D000) which
highlights their co-localization; (e0, e00, e000) higher magniﬁcation of
labeled cells (white square (E) in (c)) to show the single signals for
S100 b (e0) and venus (e00): in contrast with (d000), their ‘‘merge’’ (e000)
shows only a faint co-localization of the two signals (f, g, h, i).
Downregulation of Erk2 mRNA. Higher magniﬁcation of labeled
cells showing the speciﬁcity of downregulation in YFP
? cells infected
with the Erksh4 virus (h, i) in comparison to YFP
? cells infected with
the control virus (f, g): in (f, g) a clear ISH signal for Erk2 mRNA is
visible in control infected cells (arrow heads), as high as in YFP
-
neighboring cells (asterisks); while in (h, i) the ISH signal is absent
from YFP
? cells (arrows), although still present in neighboring YFP
-
cells (squares). k Double positive cells for YFP and Erk2 mRNA were
counted in randomly selected sections from the amygdala of the four
injected animals (n = 2 for each virus, bilaterally injected). The
number of YFP
?, Erk2
? cells was compared to the number of only
YFP
? cells. As shown in the ﬁgure, in the control injected animals
(LacZsh), the relative number of Erk2
? cells was not signiﬁcantly
different from the only YFP
?, while in the Erksh4 injected brains, this
number was signiﬁcantly reduced (ANOVA; ** P B 0.01), indicating
an efﬁcient downregulation of Erk2 also in vivo. Scale
bars = 125 lmi n( b, c); 60 lmi nD – d’’’ and E–e’’’;1 0lmi n( f,
g, h, i)
c
266 Mol Biotechnol (2009) 41:263–269extracts. As shown in Fig. 2, both Erksh4 and Erksh6 did
reduce ERK2 levels, but with different efﬁciencies.
Notably, Erksh6 also seemed to reduce partially ERK1
activity (Fig. 2a, b). Therefore, we further analyzed the
downregulation efﬁciency of both Erksh4 and Erksh6 via
quantitative RT-PCR. As shown in Fig. 2b, Erksh4 almost
completely inactivated Erk2 (4.6% remaining mRNA
level), leaving Erk1 unaffected. In contrast, the Erksh6
vector also reduced Erk1 mRNA (57.6% remaining
mRNA level). As we were interested in the speciﬁc
inactivation of Erk2, the Erksh4 cassette was further used
for in vivo experiments.
Mol Biotechnol (2009) 41:263–269 267Performance of Viral shRNA Vectors in vivo
To generate a viral shRNA expression vector the CMV-
Venus-U6Erksh4 expression unit was cloned into the
backbone of AAV2 (Fig. 1c). As control, a shRNA tar-
geting the mRNA coding for b-galactosidase (LacZ) was
used (LacZsh). As shown in Fig. 1c, a stuffer sequence
separated the U6-shRNA cassette from a second cassette
expressing the yellow ﬂuorescent protein (YFP) Venus
under control of the CMV promoter, to allow the identiﬁ-
cation of infected cells upon in vivo injections. These viral
preparations were stereotaxically injected into the LA of
adult mice. The AAV2 vectors showed a clear preferential
tropism for neurons (labeled with the speciﬁc neuronal
marker NeuN [21]) and not for glia cells (labeled with the
speciﬁc glial marker S100b [22]), as shown by immuno-
histochemistry for either DAPI/NeuN/Venus (Fig. 3b) or
DAPI/S100b/Venus (Fig. 3c); moreover, the cells infected
with the CMV-Venus-U6Erksh4 virus (YFP
?, Fig. 3h,
white arrow) showed the speciﬁc downregulation of Erk2
mRNA (Fig. 3i, red arrow), while those transduced with
the control CMV-Venus-U6LacZsh virus (YFP
?, Fig. 3f,
white arrowhead), still showed Erk2 mRNA signals
(Fig. 3g, red arrowhead). We quantiﬁed the proportion of
double labeled cells (YFP
?; Erk2
?) in comparison to the
total number of infected cells (YFP
?) cells for both
injected viral vectors in randomly selected section areas
from the LA. As shown in Fig. 3k, the relative number of
Erk2
? cells in the control injected animals (LacZsh) was
similar to the total number of only YFP
? cells
(91.7 ± 8.3%) while this number was strongly reduced in
the CMV-Venus-U6Erksh4 injected animals (Erksh4,
2.9 ± 2.2%). A one-way ANOVA analysis of the results
conﬁrmed a signiﬁcant difference between the two groups
(F(1) = 13.38; ** P B 0.01). These in vivo results con-
ﬁrmed those obtained in vitro with the qRT-PCR (Fig. 2c)
which showed the high efﬁciency of this shRNA in
silencing Erk2 mRNA.
Discussion
In this study we identiﬁed shRNAs that efﬁciently knock-
down the expression of either ERK1/2 simultaneously or
only ERK2 in vitro (Fig. 2a, b). By using AAV as deliv-
ering agent we also tested the Erk2-speciﬁc shRNA in vivo
and showed a concomitance between the downregulation
efﬁciency in vivo with that obtained in vitro (Fig. 3).
Therefore, our shRNAs can be used as tool for the further
in vivo analysis of MAP kinase signaling in the etio-
pathogenesis of neuropsychiatric diseases. In particular, we
found a shRNA, Erksh4, highly efﬁcient for the silencing
of Erk2 expression both in vitro and in vivo, that will
prove useful to further analyze the role of this gene in
speciﬁc regions of the adult brain (Figs. 2 and 3). Fur-
thermore, we found a shRNA that targets and
downregulates both Erk1 and Erk2 at the same time, but
with different relative efﬁciency (Erksh6, Fig. 2a, b); this
allows the functional analysis of both genes that are
coexpressed in most regions of the adult brain and may
exhibit functional redundancy [6]. With this shRNA we can
compensate for the lack of pharmacological agents that
inhibit ERK kinase activity and the inconvenience to
inactivate both Erk genes by gene knockout technology.
The differential relative downregulation efﬁciency makes it
a useful tool for unmasking dose-dependent effects even-
tually related to only partial inactivation of the two genes’
functions. With this shRNA it is possible to overcome the
limitation of knockout alleles that allow only for 50% or
100% gene inactivation in the heterozygote or homozygote
knockout conﬁguration, respectively. In this study we show
that AAV-mediated RNAi offers several advantages: (i) it
can target molecules which are not amenable for pharma-
cological compounds; (ii) it targets preferentially neurons
(Fig. 3b, d000), (iii) it allows the in vivo dissection of gene
function in a restricted regional and temporal manner.
These properties make it an excellent tool to unravel the
speciﬁc neuronal role of Erk2 in complex behaviors.
Nevertheless, to establish the utility of this system for
behavioral analysis, additional experiments would be nee-
ded. As compared to other viral vectors that do not show
neuronal tropism, e.g. lentivirus [23], the AAV approach
offers speciﬁc cell-type selectivity. Since also glia cells can
participate in the regulation of synaptic plasticity [24]i ti s
important to validate the tropism of a viral agent that
triggers RNAi. Our results of the AAV-CMV-Venus-
U6shRNA injections showed a clear concomitance
between gene silencing in vitro and in vivo (compare
Fig. 2 with Fig. 3). It is likely that the same concomitance
applies to the other shRNA Erksh6, overcoming limitations
of other methodologies for gradual and simultaneous gene
inhibition. To our knowledge, Erk2 has been efﬁciently
downregulated only in vitro via lentivirus-mediated RNAi
[25]. Moreover, as recently shown by [26], there is an
evident limitation not only in the availability of pharma-
cological compounds which target speciﬁcally single
molecules like the ERKs, but also in the development of
such inhibitors to analyze the function(s) of Ser/Thr kina-
ses as ERKs. In this context, our study is relevant in
demonstrating that the Erk2-speciﬁc AAV vector AAV-
CMV-Venus-U6Erksh4 provides a useful reagent for the
silencing of Erk2 in vivo, enabling to establish an alter-
native tool to study anxiety and other neuropsychiatric
disorders.
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